Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase

Hexaware Technologies appoints Shantanu Baruah as President & Global Head – Healthcare, Life Sciences, and Insurance

Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity